Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042949 | 0.91 | SLC29A1 (0.50) | SYKPOLBMEN1KMT2ASLC29A1 | |
| SCHEMBL6992013 | 0.89 | POLB (0.68) | SYKPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL12435658 | 0.85 | SYK (0.77) | SYKPOLBMEN1KMT2ACYP2D6 | |
| SCHEMBL6313608 | 0.82 | KDM4E (0.53) | POLBALDH1A1KDM4EABCB1HTR1B | |
| SCHEMBL6313695 | 0.80 | POLB (0.55) | SYKPOLBMEN1KMT2ASLC29A1 | |
| SCHEMBL21558093 | 0.79 | ABCB1 (0.45) | SYKPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2087346 | 0.78 | CYP2D6 (0.71) | SYKMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL19392831 | 0.77 | SYK (0.61) | SYKPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL4038948 | 0.77 | CYP2D6 (0.65) | SYKMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL2088116 | 0.77 | SYK (0.65) | SYKPOLBSLC29A1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | SYK 928/4885POLB 944/4885MEN1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.